Skip to main content
Full access
Letters to the Editor
Published Online: 1 December 2020

Duration of Untreated Psychosis: Getting Both the Timing and the Sample Right

To the Editor: In the April 2020 issue of the Journal, Jonas et al. (1) reported long-term data on a subgroup from the Suffolk County Mental Health Project naturalistic first-episode psychosis study. In a novel analysis, the duration of untreated psychosis (DUP) predicted trajectory of functioning relative to onset of treatment, consistent with most previous analyses of the effect of DUP (2). Crucially, however, DUP was not predictive when trajectories were defined relative to onset of psychosis. If these results were to generalize to other samples, they would have important implications for early intervention both for the first-episode psychosis and the clinical high-risk paradigms.
We note two reasons, however, that the Jonas et al. findings are unlikely to generalize to other populations. First, the authors limited analyses to the 287 of 628 patients with first-episode psychosis (45.7%) who received schizophrenia spectrum diagnoses at last observation. This post hoc exclusion very likely removed many patients with first-episode psychosis with better functional outcomes, many of whom likely had shorter DUPs, thus biasing the analysis toward the null by design. Indeed, in earlier analyses of this same cohort, the schizophrenia spectrum subgroup of first-episode psychosis patients showed both poorer outcome and longer DUP (3). Second, as described in the accompanying editorial (4), the concept of DUP itself makes most sense when patients receive adequate treatment after the end of the untreated period. Unfortunately, this did not happen here. As the authors note, treatment in this cohort was “intermittent and inconsistent.” Viewing the Suffolk County sample as atypical is further supported by a 2005 meta-analysis, in which it was one of only two (from a total of eight) samples not to show a significant effect of DUP on functioning and one of only two (from a total of 14) samples not to show a significant effect on positive symptoms (2).
Jonas et al. have done a conceptual service in pointing out that the association between DUP and illness course can potentially be affected by when the predicted course is selected to begin. We agree that if treatment delay is a modifiable risk factor for outcome, it should predict course relative to psychosis onset as well as course relative to treatment onset. The Jonas et al. sample for testing this possibility, however, is not fit for this purpose. The authors state that their findings require replication, and we agree strongly: their findings should have no policy implications until the DUP prediction of course relative to psychosis onset is investigated in other samples.

References

1.
Jonas KG, Fochtmann LJ, Perlman G, et al: Lead-time bias confounds association between duration of untreated psychosis and illness course in schizophrenia. Am J Psychiatry 2020; 177:327–334
2.
Perkins DO, Gu H, Boteva K, et al: Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005; 162:1785–1804
3.
Craig TJ, Bromet EJ, Fennig S, et al: Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series? Am J Psychiatry 2000; 157:60–66
4.
Goff DC, Li C, Thorpe L: Does early intervention improve the long-term course of schizophrenia? (editorial). Am J Psychiatry 2020; 177:288–290

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1183
PubMed: 33256446

History

Accepted: 15 June 2020
Published online: 1 December 2020
Published in print: December 01, 2020

Keywords

  1. Psychosis
  2. Early Intervention
  3. Duration of Untreated Psychosis
  4. Epidemiology
  5. Treatment Delay
  6. First-Episode Psychosis

Authors

Affiliations

Scott W. Woods, M.D. [email protected]
Department of Psychiatry and Connecticut Mental Health Center, Yale University School of Medicine, New Haven, Conn. (Woods, McGlashan); Orygen, National Centre of Excellence in Youth Mental Health, University of Melbourne, Parkville, Australia (Yung, McGorry).
Alison R. Yung, M.D.
Department of Psychiatry and Connecticut Mental Health Center, Yale University School of Medicine, New Haven, Conn. (Woods, McGlashan); Orygen, National Centre of Excellence in Youth Mental Health, University of Melbourne, Parkville, Australia (Yung, McGorry).
Patrick D. McGorry, M.D., Ph.D.
Department of Psychiatry and Connecticut Mental Health Center, Yale University School of Medicine, New Haven, Conn. (Woods, McGlashan); Orygen, National Centre of Excellence in Youth Mental Health, University of Melbourne, Parkville, Australia (Yung, McGorry).
Thomas H. McGlashan, M.D.
Department of Psychiatry and Connecticut Mental Health Center, Yale University School of Medicine, New Haven, Conn. (Woods, McGlashan); Orygen, National Centre of Excellence in Youth Mental Health, University of Melbourne, Parkville, Australia (Yung, McGorry).

Notes

Send correspondence to Dr. Woods ([email protected]).

Funding Information

National Institute of Mental Healthhttp://dx.doi.org/10.13039/100000025: R01MH120089, U01MH082022
Dr. Woods has received sponsor-initiated research funding support from Amarex, Boehringer-Ingelheim, SyneuRx, and Teva; he has served as a consultant to Boehringer-Ingelheim, the New England Research Institute, and Takeda; he is named as an inventor on a patent for a method of treating prodromal schizophrenia with glycine agonists (U.S. patent 8492418 B2); and he has received royalties from Oxford University Press. Drs. Yung, McGorry, and McGlashan report no financial relationships with commercial interests.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share